Insilico says its approach is to tackle aging and disease simultaneously makes clinical trials more commercially viable.

Insilico Alex Zhavoronkov, founder and co-chief executive of techbio company Insilico, is among the scientists who have devoted countless hours to studying aging. He has a reality-check for anyone who thinks that artificial intelligence means that the ability to double lifespans is tantalizingly close.

All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8Videos Most Popular News Most Popular Further Reading